Vol 9, No 2 (2018)
Case report
Published online: 2018-08-17

open access

Page views 784
Article views/downloads 1256
Get Citation

Connect on Social Media

Connect on Social Media

Renal cell carcinoma in patients with multiple myeloma – 2 case reports and review of literature

Agnieszka Ożańska, Marta Sobas, Magdalena Olszewska-Szopa, Tomasz Wróbel
Hematologia 2018;9(2):153-159.

Abstract

Multiple myeloma (MM) is characterized by malignant spreading of monoclonal plasma cells in bone marrow. Renal cell carcinoma (RCC) is a result of neoplastic proliferation of epithelial cells in nephron proximal convoluted tubule and forms 95% of malignant kidney’s neoplasms. There are some reports about coexistence of MM and RCC but it is a rare phenomenon. We describe two cases of patients in which during the therapy of MM, RCC was detected accidentally. Radical nephrectomy in early stage of RCC allowed complete recovery and did not interrupt the continuation of MM’s therapy. Additionally, similar cases from literature are discussed.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Eslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013; 42(10): 684–688.
  2. Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer. 2006; 107(11): 2609–2616.
  3. Hutson TE, Sonpavde G, Galsky MD. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. Clin Genitourin Cancer. 2006; 5(Suppl 1): S31–S39.
  4. Pratt G. Lenalidomide and second malignancies in myeloma patients. The Lancet Oncology. 2014; 15(3): 253–254.
  5. Shahi F, Ghalamkari M, Mirzania M, et al. A patient with multiple myeloma and renal cell carcinoma. Int J Hematol Oncol Stem Cell Res. 2016; 10(1): 56–60.
  6. Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016; 6(12): e506.
  7. Rini B, Redman B, Garcia JA, et al. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol. 2014; 25(9): 1794–1799.
  8. Xu G, Yang M, Huang J, et al. Coexistence of multiple myeloma and clear cell renal cell carcinoma: a case report and review of literature. Int J Clin Exp Pathol. 2015; 8(6): 7627–7630.
  9. Sargın G, Yavasoglu I, Doger FK, et al. A coincidence of renal cell carcinoma and hematological malignancies. Med Oncol. 2012; 29(5): 3335–3338.
  10. Cielińska S, Urbaniak-Kujda D, Gabryś K, et al. [Coincidence of multiple myeloma and renal clear cell adenocarcinoma]. Pol Arch Med Wewn. 2001; 105(2): 153–156.
  11. Nishikubo CY, Kunkel LA, Figlin R, et al. An association between renal cell carcinoma and lymphoid malignancies. Cancer. 1997; 80: 1002–1008.
  12. Choueiri TK, Baz RC, McFadden CM, et al. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int. 2008; 101(6): 712–715.
  13. Ojha RP, Evans EL, Felini MJ, et al. The association between renal cell carcinoma and multiple myeloma: insights from population-based data. BJU Int. 2011; 108(6): 825–830.
  14. Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012; 119(12): 2731–2737.
  15. US Food and Drug Administration. FDA Drug Safety Communication: Safety review update of cancer drug Revlimid (lenalidomide) and risk of developing new types of malignancies. 2012 [cited 6 March 2018].
  16. Ozturk MA, Dane F, Kaygusuz I, et al. Synchronous renal cell carcinoma and multiple myeloma: report of two cases and review of the literature. J BUON. 2009; 14(3): 511–514.
  17. Sonpavde G, Hutson TE. Recent advances in the therapy of renal cancer. Expert Opin Biol Ther. 2007; 7(2): 233–242.
  18. Johnson L, Bylund J, Strup S, et al. Concomitant renal cell carcinoma and hematologic malignancy in Immunosuppressed patients. Am J Med Sci. 2016; 351(5): 480–484.
  19. Rabbani F, Grimaldi G, Russo P. Multiple primary malignancies in renal cell carcinoma. J Urol. 1998; 160(4): 1255–1259.
  20. Beisland C, Talleraas O, Bakke A, et al. Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int. 2006; 97(4): 698–702.
  21. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012(366): 1782–1791.
  22. Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011; 118(15): 4086–4092.
  23. Palumbo A, Bringhen S, Kumar S, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014; 15(3): 333–342.



Hematology in Clinical Practice